BRIM Biotechnology, Inc. (TWSE: 6885)
Health Care · Biotechnology · TW
NT$20.70
+1.97% today · -40.7% 1Y
BRIM Biotechnology, Inc. (TWSE: 6885) operates in the Biotechnology industry within the Health Care sector. The company is valued at $86.47M and employs 32 people.
Over the last twelve months the share price has lost 40.7%, trading between 20.05 and 39.30.
Tweenvest scores BRIM Biotechnology, Inc. across four factors: quality 30/100, value 42/100, growth 100/100. Its strongest factor is growth.
6885 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $86.47M
- Revenue (TTM)
- $333.30K
- P/E
- —
- EPS
- -3.26
- Dividend yield
- —
- Beta (5Y)
- 0.73
- 52-week high
- NT$39.30
- 52-week low
- NT$20.05
- Avg volume (3M)
- —
- Shares outstanding
- 133.02M
- Employees
- 32
- Next earnings
- —
About BRIM Biotechnology, Inc.
BRIM Biotechnology, Inc. engages in the research and development of drugs and therapies to combat and cure diseases in Taiwan. The company's lead product candidate is BRM421, a neurotrophic peptide which has completed a Phase 3 clinical trial for the treatment of dry eye disease. It is also developing BRM424, a treatment option that has completed Phase 1 clinical trial for neurotrophic keratitis; BRM411, a dual target inhibitor, which has completed Phase 2 clinical trial for the treatment of glaucoma; BRM412, an anti-angiogenic eye drop that has completed Phase 2 clinical trial to treat wet age-related macular degeneration; and BRM521, a PEDF-derived short peptide that is in pre-clinical trial to relieve and repair tissue damage caused by osteoarthritis. BRIM Biotechnology, Inc. was founded in 2013 and is based in Taipei, Taiwan.
- ISIN
- TW0006885007
- Founded
- 2013
- Listed since
- Dec 16, 2024
- Exchange
- Taiwan Stock Exchange
- Currency
- TWD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €864.20 | -4.19% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $138.89 | -4.26% |
Figures last refreshed Aug 18, 2026.